![Mike Norris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mike Norris
Plus aucun poste en cours
Historique de carrière de Mike Norris
Anciens postes connus de Mike Norris
Sociétés | Poste | Début | Fin |
---|---|---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Corporate Officer/Principal | 18/10/2006 | - |
Formation de Mike Norris
University of Illinois | Graduate Degree |
University of St. Thomas (Texas) | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Venturis Therapeutics, Inc.
![]() Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Bourse
- Insiders
- Mike Norris
- Expérience